Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORA: Everolimus and Docetaxel in Head and Neck Cancer
NCT01313390Phase 2Terminated
- Sponsor
- University College London
- Start
- Jun 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by University College London. Primary endpoints: Maximum-tolerated dose and recommended phase II dose, Safety and tolerability and 1 more. Started Jun 2009; status: terminated.
02
Drugs
everolimus
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01313390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313390.